Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • USFDA nod to Reblozyl,...

    USFDA nod to Reblozyl, Celgene's rare blood disorder drug

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-11T13:13:35+05:30  |  Updated On 11 Nov 2019 1:13 PM IST
    USFDA nod to Reblozyl, Celgenes rare blood disorder drug

    The U.S. Food and Drug Administration said on Friday it had approved treatment for a rare blood disorder from Celgene Corp, which is in the process of being bought by Bristol-Myers Squibb Co.


    Reblozyl, which has been jointly developed by Celgene and Acceleron Pharma Inc, is meant for treatment of anemia in patients with beta-thalassemia, who require regular red blood cell transfusions.


    Beta thalassemia is an inherited disorder that reduces the production of hemoglobin in blood, which can lead to lack of oxygen in many parts of the body and anemia, the FDA said.


    Read Also: Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court


    The approval is a shot in the arm for Celgene as its flagship multiple myeloma drug, Revlimid awaits loss of exclusivity starting 2022.


    Treatment for people with beta thalassemia often consists of lifelong regimens of chronic blood transfusions for survival and treatment for iron overload due to the transfusions.


    "Today's approval provides patients with a therapy that, for the first time, will help decrease the number of blood transfusions", FDA's Richard Pazdur said in a statement. Celgene said the drug is expected to be available a week following the approval.


    Read Also: Amgen to pay hefty $13.4 billion for buying Celgene psoriasis drug Otezla

    Acceleron PharmaBeta thalassemiaBristol-Myers Squibb CoCelgene Corphemoglobinpharmapharma companypharma newsrare blood disorderReblozylUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok